Keymed said AstraZeneca has initiated a multi-center Phase III trial of AZD0901 in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive and HER2-negative advanced/metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. The first subject dosed in the trial triggered a milestone payment of USD 45 million, which the group said it has received. Keymed added that KYM, the unit developing CMG901/AZD0901, is 70% owned by the group, with the remaining 30% held by Innocube under Lepu Biopharma’s control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12046806), on March 10, 2026, and is solely responsible for the information contained therein.